Status:
UNKNOWN
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Peking University People's Hospital
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Myelodysplastic Syndrome
Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion. In this...
Detailed Description
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion. Our pre...
Eligibility Criteria
Inclusion
- RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT
- 14-65 years
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision)
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT04713956
Start Date
January 15 2021
End Date
July 31 2024
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515